Cardio Diagnostics Holdings Inc. (CDIO) Cash on Hand per Share

Corporate emblem and logo of Cardio Diagnostics Holdings (CDIO)

Management at Cardio Diagnostics (CDIO) possesses a strong scientific background and is currently optimizing expenses amid capital shortages. The company's revenue is based on the sale of AI tests for detecting cardiac pathologies via blood analysis. Cash per share demonstrates genuine financial stability, where the value of 1.33 describes the current level. This enables the scaling of autonomous IT systems that automate epigenetic diagnostics.

Cardio Diagnostics Holdings (CDIO) - Cash per Share from 04/28/2023 to 11/20/2026

Comprehensive metric breakdowns and analytics for Cardio Diagnostics Holdings, Inc. (CDIO)

- market value and analyst target forecast:
- cash position and cash flow details:
Manufactured product of Cardio Diagnostics Holdings Inc.

Cardio Diagnostics (CDIO) is transforming cardiology by identifying heart attack risks through epigenetic blood analysis. The trend in cash per share demonstrates the volume of liquid reserves available for each unit of equity. This indicator measures financial stability by excluding market volatility from the valuation. A high level of funds minimizes the probability of bankruptcy, creating a defensive layer for innovation. However, excessive liquidity may constrain the asset's overall return.